Hims & Hers Health, Inc. Class Action Lawsuit Deadline

Strategic Insights -

Investors who purchased Hims & Hers Health, Inc. (HIMS) securities between April 29, 2025, and June 23, 2025, inclusive, may be eligible to participate in the class action lawsuit. The company announced a long-term collaboration with Novo Nordisk on April 29, 2025, but Novo Nordisk terminated the partnership on June 23, 2025, citing Hims' deceptive promotion and sale of illegitimate, knockoff versions of Wegovy. As a result, the company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025.

Key Takeaways:

  • The class action lawsuit alleges that Hims & Hers Health, Inc. made materially false and/or misleading statements about its business, operations, and prospects, including the sale of illegitimate, knockoff versions of Wegovy.
  • Novo Nordisk terminated its partnership with Hims due to the company's deceptive promotion and sale of knockoff versions of Wegovy, which put patient safety at risk.
  • Investors who purchased Hims securities between April 29, 2025, and June 23, 2025, inclusive, may be eligible to participate in the class action lawsuit.
  • The lawsuit alleges that Hims failed to disclose material adverse facts about its business, including the sale of knockoff versions of Wegovy.
  • The company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume.

Statistics:

  • $22.24: The amount by which the company's share price fell on June 23, 2025.
  • 34.6%: The decrease in the company's share price on June 23, 2025.
  • $41.98: The closing price of the company's shares on June 23, 2025.
  • April 29, 2025: The date on which Hims announced a long-term collaboration with Novo Nordisk.
  • June 23, 2025: The date on which Novo Nordisk terminated its partnership with Hims.

Sources:

  • Glancy Prongay & Murray LLP, Email: [cl@glancylaw.com](mailto:cl@glancylaw.com), Telephone: 310-201-9150, Toll-Free: 888-773-9224
  • Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100 Los Angeles, CA 90067
  • Novo Nordisk press release, dated June 23, 2025
  • Hims & Hers Health, Inc. press release, dated April 29, 2025